Edinburgh BioQuarter

An image of the Edinburgh BioQuarter development masterplan.
Plans for the expansion of Edinburgh BioQuarter. (copyright Edinburgh BioQuarter).

Edinburgh BioQuarter is a 65 hectare (160 acre) healthcare and medical research campus in the Little France neighbourhood in south-east Edinburgh. 8,000 people currently work at Edinburgh BioQuarter, including clinicians, academics, and commercial researchers. Research carried out at Edinburgh BioQuarter focuses on major diseases. There is a strong focus on translational "bench to bedside" medicine, converting novel research into new treatments.

Companies with a presence at Edinburgh BioQuarter include pharmaceuticals giant GSK; medical devices companies CALCiViS and SIRAKOSS; bio-manufacturer Nandi Proteins; contract research organisation Aquila BioMedical, contract manufacturing organisation Roslin Cells; and bioinformatics specialist Fios Genomics.

Healthcare and medical research facilities

Major investment has been carried out to date, with Edinburgh BioQuarter home to the following purpose-built healthcare and medical research facilities:

Expansion of Edinburgh BioQuarter

A £750 million expansion of Edinburgh BioQuarter that would evolve the area into a vibrant mixed-use neighbourhood is planned. The expansion would deliver additional healthcare and research space, along with housing, a hotel, and retail and leisure space, creating around 9,000 new jobs. The expansion is being take forward as a partnership between the City of Edinburgh CouncilNHS Lothian, Scottish Enterprise, and the University of Edinburgh. A development partner is being procured to take forward the development. More information can be found on the Public Contracts Scotland website.



Contact us

Is your organisation interested in locating or expanding in Edinburgh? If so, please get in touch to discuss how we can provide free and confidential support for your project.

Follow us on social media